| Literature DB >> 25691661 |
M Christiane Brahimi-Horn1, Sandra Lacas-Gervais2, Ricardo Adaixo3, Karine Ilc1, Matthieu Rouleau4, Annick Notte5, Marc Dieu5, Carine Michiels5, Thibault Voeltzel6, Véronique Maguer-Satta6, Joffrey Pelletier1, Marius Ilie7, Paul Hofman7, Bénédicte Manoury8, Alexander Schmidt3, Sebastian Hiller3, Jacques Pouysségur9, Nathalie M Mazure10.
Abstract
The oxygen-limiting (hypoxic) microenvironment of tumors induces metabolic reprogramming and cell survival, but the underlying mechanisms involving mitochondria remain poorly understood. We previously demonstrated that hypoxia-inducible factor 1 mediates the hyperfusion of mitochondria by inducing Bcl-2/adenovirus E1B 19-kDa interacting protein 3 and posttranslational truncation of the mitochondrial ATP transporter outer membrane voltage-dependent anion channel 1 in hypoxic cells. In addition, we showed that truncation is associated with increased resistance to drug-induced apoptosis and is indicative of increased patient chemoresistance. We now show that silencing of the tumor suppressor TP53 decreases truncation and increases drug-induced apoptosis. We also show that TP53 regulates truncation through induction of the mitochondrial protein Mieap. While we found that truncation was independent of mitophagy, we observed local microfusion between mitochondria and endolysosomes in hypoxic cells in culture and in patients' tumor tissues. Since we found that the endolysosomal asparagine endopeptidase was responsible for truncation, we propose that it is a readout of mitochondrial-endolysosomal microfusion in hypoxia. These novel findings provide the framework for a better understanding of hypoxic cell metabolism and cell survival through mitochondrial-endolysosomal microfusion regulated by hypoxia-inducible factor 1 and TP53.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25691661 PMCID: PMC4387213 DOI: 10.1128/MCB.01402-14
Source DB: PubMed Journal: Mol Cell Biol ISSN: 0270-7306 Impact factor: 4.272